ClinicalTrials.gg
RecruitingNCT06755450ADITI-1Updated Jan 13, 2026

Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma

A Phase 1 interventional study of AUR112 in Relapsed Advanced Lymphomas, sponsored by Aurigene Discovery Technologies Limited. Recruiting at 19 sites in India. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Aurigene Discovery Technologies Limited (part of Dr. Reddy's Laboratories Limited) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies in Lymphoma, Non-Hodgkin with a site in India — 2 open to participants now, 3 under way, 1 of them phase 3. Lymphoma, Non-Hodgkin · India.

Planned enrollment
12th of 15
40 · median 256
Started
2025
the only one that year
Phase 1
4 of 16
1 open now
Registered
16th of 16
by date
Lead sponsor
4 of 16
Aurigene Discovery Technologies Limited

Among the 16 studies in Lymphoma, Non-Hodgkin with a site in India, this one is the 12th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 1, and was the 16th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

2 of the 16 studies in Lymphoma, Non-Hodgkin with a site in India are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Lymphoma, Non-Hodgkin with a site in India, or all of them as a file.
02

Study summary

A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1)

Read the detailed description

The main objective of Part 1 will be to evaluate the safety and tolerability of the study drug AUR112.

Dose escalation of single agent AUR112 will be conducted in the classic 3+3 design. Safety including Dose Limiting Toxicities (DLTs), PK, and PD will be assessed at each dose. Dose escalation will continue until safety limits are reached or the escalation will stop earlier if PK/PD data suggest that a biologically active dose has reached.

The objective is to determine dose(s) which will be investigated in future trials.

03

Conditions studied

  • Relapsed Advanced Lymphomas

Keywords

  • Non-Hodgkin Lymphoma (NHL)
  • Hodgkin Lymphoma
  • Relapse Advanced Lymphomas
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females ≥ 18 years of age
  2. (ECOG) Performance status of 0 or 1
  3. Acceptable bone marrow and organ function at screening as described below:

    1. ≥ 1000/μL (without WBC growth factor support)
    2. count: For patients with CLL ≥ 50,000/μL; For patients with lymphomas ≥ 75,000/μL without bone marrow involvement and ≥ 50,000/μL with bone marrow involvement. These thresholds should be qualified without platelet transfusion support.
    3. ≥ 9 g/dL (RBC Transfusion is allowed to achieve this Hb)
    4. Total ≤ 1.5 x ; (Patients with known Gilbert's syndrome are allowed with a Total Bilirubin ≤ 2.5 x ULN)
    5. (SGOT) ≤ 3 x ULN (≤ 5 × ULN if known liver )
    6. ALT (SGPT) ≤ 3 x ULN (≤ 5 × ULN if known liver metastases)
    7. (CrCl) ≥ 60 mL/min (either measured or estimated by the Cockcroft-Gault formula). (Cockcroft-Gault formula for estimated creatinine clearance [eCrCl]: eCrCl = [140- Age] × Weight [kg] × [0.85 if Female] / [72 × serum creatinine (mg/dL)]).
  4. Ability to swallow and retain oral medications
  5. Histopathological diagnosis of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) or Hodgkin disease. Note:

5a. The lymphoma should be either in Stage III or IV according to Lugano classification (Cheson et al. 2014) at screening. 5b. The lymphomas included in this study must fall within one of the following 2017 World Health Organization categories except lymphoma mentioned in Exclusion criterion #5:

  • Mature B-cell neoplasms (excluding plasma cell neoplasms, heavy chain disease, and primary central nervous system [CNS] lymphoma).
  • Mature T- and NK-cell neoplasms.
  • Hodgkin lymphomas 5c. The CLL should be Binet Stage C/Rai stage III or IV, as per the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines (Hallek et al. 2018).

    6. In the case of subjects who have lymphoma for which high-dose chemotherapy and stem cell transplantation (HDASCT) is considered a standard curative therapy, eligibility for this study requires that the subject's disease has after HDASCT, or the subject is not eligible for HD-ASCT, or that the subject has refused HD-ASCT.

    7. In the case of patients who have lymphoid for which CAR-T therapy is indicated, eligibility for this study requires that the disease has relapsed after CAR-T, or the patient is not eligible for CAR-T, or the patient has refused CAR-T, or the CAR-T is not available locally.

    8. Evidence of as per Lugano Criteria for Lymphoma (Cheson et al. 2014) or evidence of measurable disease as per iwCLL Criteria for CLL (Hallek et al. 2018). Note: Patients with Small Lymphocytic Lymphoma (SLL) alone or in combination with CLL are allowed.

    9. Standard curative measures do not exist, and the patient must have exhausted all effective therapies available locally. The patients must have relapsed or refractory to at least 2 for NHL or CLL, or Hodgkin disease.

Note:

  • Any cancer patient with access to any effective therapy locally must not be enrolled.
  • Patients with CLL should have documented evidence for progressive or symptomatic disease (active disease) and must have indications for treatment (Hallek et al 2018).
  • Patients with indolent lymphomas also must have indications for treatment, such as the GELF (Brice et al 1997) or BNLI criterion (Ardeshna et al 2003)

Exclusion criteria

Exclusion Criteria:

  1. Systemic anti-cancer therapy, such as chemotherapy, biological therapy, or immunomodulatory drug therapy received within the past 28 days or 5 half-lives, whichever is longer, from the Cycle 1 Day 1 of the study. Note: Concomitant use of low dose prednisone (up to 10 mg/day) is allowed
  2. Presence of an acute or chronic toxicity resulting from prior anticancer treatment, with the exception of alopecia or nail changes, that has not resolved to Grade ≤ 1, as determined by v 5.0. 1
  3. Definitive Radiotherapy within the last 21 days of Cycle 1 Day 1 (limited field palliative radiation is allowed and no restrictions during the screening period or during the trial).
  4. Use of any agent within 28 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1
  5. Patients with Burkitt's lymphoma, Burkitt-like lymphoma, posttransplant lymphoproliferative disease, primary mediastinal large-B cell lymphoma, cutaneous lymphomas, mycosis fungoides (MF), or Sezary syndrome (SS).
  6. Known symptomatic or untreated or recently treated (≤ 6 months of screening) central nervous system (CNS) lymphoma. Patients with previously treated (> 6 months of screening) CNS lymphoma and are now stable and asymptomatic, from CNS perspective, are allowed.
  7. Patients with lymphoma that requires immediate cytoreductive therapy.
  8. Patients with low-grade lymphoma or indolent lymphoma that does not meet conventional criteria (Jeong SH, 2022) for requiring treatment.
  9. Patients on drugs which are inhibitors of P-gp or BCRP or UGT1A1 and when these drugs cannot be discontinued from at least one week prior to Cycle 1 Day 1. Note: These drugs will be prohibited during Cycle 1 of therapy.
  10. Major surgery ≤ 28 days from Cycle 1 Day 1 (major surgery is defined as a procedure requiring general anesthesia)
  11. Active infection requiring systemic therapy. Note: Prophylactic use of antibiotics is allowed. Any infection detected during screening period which is resolved adequately according to investigator before the Cycle 1 Day 1, is allowed.
  12. Known to be (HIV) positive or have an acquired immunodeficiency syndrome-related illness.
  13. Known active or chronic (HBsAg +ve) or infection (HCV antibody +ve).
  14. The patient who is expected to require any other form of antineoplastic therapy or targeted therapy while on study
  15. . Uncontrolled congestive heart failure ( [NYHA] Class 2-4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, or , or pulmonary embolism within 3 months prior to Cycle 1 Day 1.
  16. Ongoing cardiac dysrhythmias requiring treatment of any grade or treatment of cardiac dysrhythmias in past 3 months, before Cycle 1 Day 1.
  17. (Fridericia) interval >470 ms on at screening and/or at Cycle 1 Day 1 pre-dose.
  18. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or significant gastritis, active bleeding diatheses, presence of any major medical illness (e.g. renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or psychiatric illness/social situations or laboratory / ECG abnormalities at screening, any or a combination of illnesses, which, in the opinion of the PI, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study.
  19. Current swab-positive or suspected (under investigation) Covid19 infection or fever and other signs or symptoms suggestive of Covid-19 infection with recent contact of person(s) with confirmed Covid-19 infection, at screening or Cycle 1 Day 1.
  20. History of another primary within 5 years prior to starting study drug, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study.
  21. Positive pregnancy test for women of (WOCBP) at the screening or enrolment visit.
  22. Lactating women or WOCBP or a man with a partner who has childbearing potential, who are neither surgically sterilized nor willing to use reliable methods(hormonal contraceptive, IUD, or any double combination of male or female condom, spermicidal gel, diaphragm, sponge, cervical cap) during the screening period, while on AUR112 and at least 28 days after last dose
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    AUR112

    Experimental: AUR112, 100mg to 1200mg Currently, six (6) planned dose levels are 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, and 1200 mg once daily (QD). AUR112: Once daily

    Drug: AUR112

Interventions

  • DrugAUR112

    Once daily

06

What researchers measure

Primary outcomes

  1. First cycle Dose Limiting Toxicities (DLT).

    Number of participants with dose limiting toxicities (DLT) taking AUR112

    Time frame: 28 days (Cycle 1)

  2. Safety of AUR112 as measured by the number of participants with treatment related adverse events (AE) graded according to NCI CTCAE version 5.0

    The assessment of safety was based on the frequency of deaths, adverse event (AE), serious adverse event (SAE)s leading to discontinuation of study drug, and abnormalities in specific laboratory assessments. AEs and laboratory values will be graded for severity according to NCI CTCAE version 5.0

    Time frame: 28 days

  3. To determine the doses to be recommended for evaluation in future studies.

    Determine selected dose(s) to be studied in future clinical trials

    Time frame: 28 days

  4. Pharmacokinetics: Maximum concentration (Cmax)

    Maximum concentration of AUR112

    Time frame: [Time Frame: Day 1 and Day 15]

  5. Pharmacokinetics: Time to Maximum concentration (Tmax)

    Tmax in hours

    Time frame: [Time Frame: Day 1 and Day 15]

  6. Pharmacokinetics: Area under the curve (AUC)

    Area under the curve (AUC) of AUR 112 in h\* mcg/mL

    Time frame: [Time Frame: Day 1 and Day 15]

  7. Pharmacokinetics: Mean Residence Time (MRT)

    Average time the drugs stays in the body

    Time frame: [Time Frame: Day 1 and Day 15]

  8. Pharmacokinetics: Terminal elimination half-life

    Terminal elimination half-life of AUR 112 in hours

    Time frame: [Time Frame: Day 1 and Day 15]

  9. Maximum concentration (Cmax) administered under fasting/fed condition

    Compare in fast and fed conditions

    Time frame: [Time Frame: Day 8 and Day 9]

  10. Time to Maximum concentration (Tmax) administered under fasting/fed condition

    Compare Tmax in fast and fed conditions

    Time frame: [Time Frame: Day 8 and Day 9]

  11. Area under curve (AUC) administered under fasting/fed condition

    Compare AUC in fast and fed conditions

    Time frame: [Time Frame: Day 8 and Day 9]

Other outcomes

  1. Exploratory endpoint: Expression of cytokines

    Pharmacodynamic marker: CYTOKINE MARKERS analysis

    Time frame: [Time Frame: Day 1, Day 2, and Day 15]

  2. Exploratory endpoint: Gene expression profile

    Pharmacodynamic marker: Gene expression analysed from whole blood

    Time frame: [Time Frame: Day 1, Day 2, and Day 15]

  3. Exploratory endpoint- Efficacy assessments, Overall Response Rate

    Efficacy assessments-Overall Response Rate

    Time frame: [Time Frame: Through study completion, an average of 1 year]

  4. Exploratory endpoint- Efficacy assessments, Duration of Response

    Efficacy assessments- Duration of Response

    Time frame: [Time Frame: Through study completion, an average of 1 year]

  5. Exploratory endpoint- Efficacy assessments, Progression Free Survival (PFS)

    Efficacy assessments- Progression Free Survival (PFS)

    Time frame: [Time Frame: Through study completion, an average of 1 year]

07

Study locations

12 of 19 sites recruiting
  • Sir Sayajirao General Hospital (SSG)
    Vadodara, Gujarat 390001, India
    Active, not recruiting

    Not enrolling at this site.

  • National Cancer Institute , All India Institute of Medical Sciences
    Jhajjar, Haryana 124105, India
    Recruiting
  • Health Care Global Enterprises
    Bangalore, Karnataka 560027, India
    Active, not recruiting

    Not enrolling at this site.

  • Srinivasam Cancer Care Multi Speciality Hospitals India Pvt Ltd. , Bangalore 560072.
    Bangalore, Karnataka 560027, India
    Recruiting
    • Dr. K.C. Lakshmaiah, MBBS, MD, DM · Contactkcluck@gmail.com · +91 9448055949
  • Jeevan Amrut Hematology Center, Aurangabad
    Aurangabad, Maharashtra 431001, India
    Recruiting
  • HCG Cancer Centre
    Nagpur, Maharashtra 440026, India
    Recruiting
  • Sahyadri Hospital Private Limited
    Pune, Maharashtra 410014, India
    Recruiting
  • Novo Solitaire Care
    Pune, Maharashtra 411014, India
    Recruiting
  • Armed Forces Medical College
    Pune, Maharashtra 411040, India
    Not yet recruiting
    • Dr.Uday Yanamandra, MBBS, MD, DM,DNB · Contactudayj2@gmail.com · 8195035551
  • Onco Life Cancer, Centre, Satara
    Satara, Maharashtra 415519, India
    Recruiting
  • Sunact Cancer Institute Pvt. Ltd
    Thane, Maharashtra 400 615, India
    Recruiting
  • Siddharth Gupta Memorial Hospital,
    Wardha, Maharashtra 442107, India
    Recruiting
  • Tata Memorial Hospital
    Pārel, Mumbai 400012, India
    Recruiting
  • AIIMS, New Delhi
    New Delhi, New Delhi 110029, India
    Active, not recruiting

    Not enrolling at this site.

  • Max Super Specialty Hospital
    Sāket, New Delhi 110017, India
    Active, not recruiting

    Not enrolling at this site.

  • AIIMS, Bhubaneswar
    Bhubaneswar, Odisha 751019, India
    Recruiting
  • Somani Hospital
    Jaipur, Rajasthan 302019, India
    Active, not recruiting

    Not enrolling at this site.

  • AIIMS, Rishikesh
    Rishikesh, Uttarakhand 249203, India
    Recruiting
  • Tata Medical Centre
    Kolkata, West Bengal 700160, India
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's planned 24 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2024
First posted
Jan 1, 2025
StartActual
Jan 15, 2025
Primary completionEst.
Jan 15, 2027
CompletionEst.
Jan 15, 2028
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06755450
Responsible party
Sponsor
First posted
Jan 1, 2025
Start date
Jan 15, 2025
Primary completion
Jan 15, 2027 (estimated)
Completion
Jan 15, 2028 (estimated)
Last update
Jan 13, 2026

Study contacts

Suchit D Kumbhare
Contact
suchit_k@aurigene.com
+91- 8104730078
Suresh O
Contact
suresh_o@aurigene.com
+91-9866225593
Akhil Kumar
principal investigator · Aurigene Oncology Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion